Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-22T23:54:44.836Z Has data issue: false hasContentIssue false
  • English
  • Français

Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis

Published online by Cambridge University Press:  25 January 2011

Graham Mowatt ,
James N'Dow ,
Luke Vale ,
Ghulam Nabi ,
Charles Boachie ,
Jonathan A. Cook ,
Cynthia Fraser  and
T. R. Leyshon Griffiths
Graham Mowatt
Affiliation:
University of Aberdeen
James N'Dow
Affiliation:
University of Aberdeen and Aberdeen Royal Infirmary
Luke Vale
Affiliation:
University of Aberdeen
Ghulam Nabi
Affiliation:
University of Dundee and Ninewells Hospital
Charles Boachie
Affiliation:
University of Aberdeen
Jonathan A. Cook
Affiliation:
University of Aberdeen
Cynthia Fraser
Affiliation:
University of Aberdeen
T. R. Leyshon Griffiths
Affiliation:
University of Leicester and Leicester General Hospital
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: The aim of this study was to assess the test performance and clinical effectiveness of photodynamic diagnosis (PDD) compared with white light cystoscopy (WLC) in people suspected of new or recurrent bladder cancer.

Methods: A systematic review was conducted of randomized controlled trials (RCTs), nonrandomized comparative studies, or diagnostic cross-sectional studies comparing PDD with WLC. Fifteen electronic databases and Web sites were searched (last searches April 2008). For clinical effectiveness, only RCTs were considered.

Results: Twenty-seven studies (2,949 participants) assessed test performance. PDD had higher sensitivity than WLC (92 percent, 95 percent confidence interval [CI], 80–100 percent versus 71 percent, 95 percent CI, 49–93 percent) but lower specificity (57 percent, 95 percent CI, 36–79 percent versus 72 percent, 95 percent CI, 47–96 percent). For detecting higher risk tumors, median range sensitivity of PDD (89 percent [6–100 percent]) was higher than WLC (56 percent [0–100 percent]) whereas for lower risk tumors it was broadly similar (92 percent [20–95 percent] versus 95 percent [8–100 percent]). Four RCTs (709 participants) using 5-aminolaevulinic acid (5-ALA) as the photosensitising agent reported clinical effectiveness. Using PDD at transurethral resection of bladder tumor (TURBT) resulted in fewer residual tumors at check cystoscopy (relative risk [RR], 0.37, 95 percent CI, 0.20–0.69) and longer recurrence-free survival (RR, 1.37, 95 percent CI, 1.18–1.59), compared with WLC.

Conclusions: PDD detects more bladder tumors than WLC, including more high-risk tumors. Based on four RCTs reporting clinical effectiveness, 5-aminolaevulinic acid–mediated PDD at TURBT facilitates a more complete resection and prolongs recurrence-free survival.

Keywords

Systematic reviewMeta-analysisDiagnostic testsBladder cancer
Type
ASSESSMENTS
Information
International Journal of Technology Assessment in Health Care , Volume 27 , Issue 1 , January 2011 , pp. 3 - 10
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Babjuk, M, Oosterlinck, W, Sylvester, R, et al. Guidelines on TaT1 (non-muscle-invasive) bladder cancer. Arnhem: European Association of Urology; 2009. http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/TaT1_BC.pdf (accessed January 2010).Google Scholar
2. Babjuk, M, Soukup, V, Petrik, R, Jirsa, M, Dvoracek, J. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int. 2005;96:798–802.CrossRefGoogle ScholarPubMed
3. Cancer Research UK. UK bladder cancer statistics. 2010. http://info.cancerresearchuk.org/cancerstats/types/bladder/?a=5441 (accessed January 2010).Google Scholar
4. Hendricksen, K, Moonen, PM, der Heijden, AG, Witjes, JA. False-positive lesions detected by fluorescence cystoscopy: Any association with p53 and p16 expression? World J Urol. 2006;24:597–601.CrossRefGoogle ScholarPubMed
5. Jichlinski, P, Wagnieres, G, Forrer, M, et al. Clinical assessment of fluorescence cytoscopy during transurethral bladder resection in superficial bladder cancer. Urol Res. 1997;25:S3–S6.CrossRefGoogle Scholar
6. Kausch, I, Sommerauer, M, Montorsi, F, et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: A systematic review and cumulative analysis of prospective studies. Eur Urol. 2010;57:595–606.CrossRefGoogle ScholarPubMed
7. Koenig, F, McGovern, FJ, Larne, R, et al. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid. BJU Int. 1999;83:129–135.CrossRefGoogle ScholarPubMed
8. Kriegmair, M, Zaak, D, Rothenberger, KH, et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol. 2002;168:475–478.CrossRefGoogle ScholarPubMed
9. Leeflang, MM, Deeks, JJ, Gatsonis, C, Bossuyt, PM, Cochrane Diagnostic Test Accuracy Working Group. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149:889–897.Google Scholar
10. Macaskill, P. Empirical Bayes estimates generated in a hierarchical summary ROC analysis agreed closely with those of a full Bayesian analysis. J Clin Epidemiol. 2004;57:925–932.CrossRefGoogle Scholar
11. Masters, JRW, Popert, RJM, Thompson, PM, et al. Intravesical chemotherapy with epirubicin: A dose response study. J Urol. 1999;161:1490–1493.CrossRefGoogle ScholarPubMed
12. Mowatt, G, Zhu, S, Kilonzo, M, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess. 2010;14:1–331, iii–iv.CrossRefGoogle ScholarPubMed
13. Sangar, VK, Ragavan, N, Matanhelia, SS, Watson, MW, Blades, RA. The economic consequences of prostate and bladder cancer in the UK. BJU Int. 2005;95:59–63.CrossRefGoogle ScholarPubMed
14. Stenzl, AS, Roessler, WR, Fradet, YF, et al. HEXVIX fluorescence cystoscopy improves detection and resection of papillary bladder cancer and reduces early recurrence: A multicentre prospective randomized trial. Abstract 1010. Eur Urol Suppl. 2009;8:373.CrossRefGoogle Scholar
15. Sylvester, RJ, Oosterlinck, W. An immediate instillation after transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: Has the evidence changed? Eur Urol. 2009;56:43–45.CrossRefGoogle ScholarPubMed
16. Sylvester, RJ, Oosterlinck, W, Van Der Meijden, APM. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials. J Urol. 2004;171:2186–2190.CrossRefGoogle ScholarPubMed
17. Whiting, P, Rutjes, AW, Reitsma, JB, Bossuyt, PM, Kleijnen, J. The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.CrossRefGoogle ScholarPubMed
18. Zaak, D, Karl, A, Knuchel, R, et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int. 2005;96:217–222.CrossRefGoogle ScholarPubMed
Supplementary material: File

Mowatt supplementary material

Tables 1-4

Download Mowatt supplementary material(File)
File 60.6 KB